# Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

> **NCT03425526** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (estimated)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Immunocompromised

## Interventions

- **BIOLOGICAL:** Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

## Key facts

- **NCT ID:** NCT03425526
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-03-15
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03425526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03425526, "Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03425526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*